{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:54:53Z","timestamp":1783619693166,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024855","name":"Agency for Cultural Affairs, Government of Japan","doi-asserted-by":"publisher","award":["JP21mk0101159"],"award-info":[{"award-number":["JP21mk0101159"]}],"id":[{"id":"10.13039\/501100024855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024855","name":"Agency for Cultural Affairs, Government of Japan","doi-asserted-by":"publisher","award":["JP21mk0101159"],"award-info":[{"award-number":["JP21mk0101159"]}],"id":[{"id":"10.13039\/501100024855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This research aimed to identify significant prognostic factors that interact with the treatment effect of capecitabine and oxaliplatin (CapeOX), based on individual patient data from the CLASSIC study (NCT00411229), which evaluated the efficacy of adjuvant chemotherapy for gastric cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Stepwise variable selection of prognostic factors was performed using the Cox proportional hazards model, with patient data from 519 CapeOX-treated and 514 untreated patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>For all-cause mortality, older women (\u2265\u200955\u00a0years) with a serum albumin level\u2009\u2265\u20094.0\u00a0g\/dL were identified as significant prognostic factors interacting with CapeOX treatment, and unexpectedly, the treatment was associated with poor outcomes in this group. The prognostic significance of serum albumin levels was primarily attributed to the particularly poor survival outcomes observed in untreated patients with serum albumin\u2009&lt;\u20094.0\u00a0g\/dL. Tumor stage and lymph node status were prognostic factors that interacted with treatment for disease-free survival (DFS). The results showed that in patients with tumor stage (T)\u2009\u2265\u2009T3 and lymph node metastasis (N)\u2009&lt;\u2009N2, improvement in DFS with CapeOX was not significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>As this was a post-hoc analysis, the results should be interpreted as hypothesis-generating rather than definitive. Nevertheless, the findings suggest the need for a more detailed consideration of patient baseline characteristics when determining the adjuvant chemotherapy strategy for gastric cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12029-025-01239-3","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T02:49:05Z","timestamp":1750992545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvant Chemotherapy for Gastric Cancer may Worsen Prognosis in Elderly Women: Retrospective Analysis of Individual Patient Data from the CLASSIC Study"],"prefix":"10.1007","volume":"56","author":[{"given":"Fumitaka","family":"Noji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"1239_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1239_CR2","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.3748\/wjg.v12.i20.3237","volume":"12","author":"A Gallo","year":"2006","unstructured":"Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol. 2006;12:3237\u201342. https:\/\/doi.org\/10.3748\/wjg.v12.i20.3237.","journal-title":"World J Gastroenterol"},{"key":"1239_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.2010.534","volume":"303","author":"X Paoletti","year":"2010","unstructured":"GASTRIC (Global Advanced\/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729\u201337. https:\/\/doi.org\/10.1001\/jama.2010.534.","journal-title":"JAMA"},{"key":"1239_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ags3.12284","volume":"3","author":"S Komatsu","year":"2019","unstructured":"Komatsu S, Otsuji E. Essential updates 2017\/2018: recent topics in the treatment and research of gastric cancer in Japan. Ann Gastroenterological Surg. 2019;3:581\u201391. https:\/\/doi.org\/10.1002\/ags3.12284.","journal-title":"Ann Gastroenterological Surg"},{"key":"1239_CR5","unstructured":"National Comprehensive Cancer Network. Gastric cancer, version 2. NCCN Clinical Practice Guidelines in Oncology. 2022."},{"key":"1239_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa010187","volume":"345","author":"JS Macdonald","year":"2001","unstructured":"Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725\u201330. https:\/\/doi.org\/10.1056\/NEJMoa010187.","journal-title":"N Engl J Med"},{"key":"1239_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"},{"key":"1239_CR8","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"key":"1239_CR9","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"1","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;1:1810\u201320.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1239_CR10","first-page":"110","volume":"33","author":"M Sasako","year":"2006","unstructured":"Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Adjuvant chemotherapy using S-1 for curatively resected gastric cancer-the nationwide clinical trial. Gan To Kagaku Ryoho. 2006;33(Suppl 1):110\u20136.","journal-title":"Gan To Kagaku Ryoho"},{"key":"1239_CR11","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"20","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;20:1296\u2013304.","journal-title":"J Clin Oncol"},{"key":"1239_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s10120-021-01224-2","volume":"25","author":"Y Kakeji","year":"2022","unstructured":"Kakeji Y, Yoshida K, Kodera Y, et al. Three year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S 1 plus docetaxel versus S 1 alone in stage III gastric cancer. JACCRO-GC 07. Gastric Cancer. 2022;25:188\u201396. https:\/\/doi.org\/10.1007\/s10120-021-01224-2.","journal-title":"Gastric Cancer"},{"key":"1239_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (Classic): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(11)61873-4.","journal-title":"Lancet"},{"key":"1239_CR14","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (Classic): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(14)70473-5.","journal-title":"Lancet Oncol"},{"key":"1239_CR15","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.ejca.2014.01.029","volume":"50","author":"A Ferro","year":"2014","unstructured":"Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Worldwide trends in gastric cancer mortality (1980\u20132011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:1330\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.029.","journal-title":"Eur J Cancer"},{"key":"1239_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2407-14-150","volume":"14","author":"D Satg\u00e9","year":"2014","unstructured":"Satg\u00e9 D, Sauleau EA, Jacot W, Raffi F, Az\u00e9ma B, Bouyat JC, El Hage AN. Age and stage at diagnosis: a hospital series of 11 women with intellectual disability and breast carcinoma. BMC Cancer. 2014;14:150. https:\/\/doi.org\/10.1186\/1471-2407-14-150.","journal-title":"BMC Cancer"},{"key":"1239_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jjco\/hyx094","volume":"47","author":"FL Kinoshita","year":"2017","unstructured":"Kinoshita FL, Ito Y, Morishima T, Miyashiro I, Nakayama T. Sex differences in lung cancer survival: long-term trends using population-based cancer registry data in Osaka, Japan. Jpn J Clin Oncol. 2017;47:863\u20139. https:\/\/doi.org\/10.1093\/jjco\/hyx094.","journal-title":"Jpn J Clin Oncol"},{"key":"1239_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","volume":"64","author":"M Arnold","year":"2015","unstructured":"Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64:381\u20137. https:\/\/doi.org\/10.1136\/gutjnl-2014-308124.","journal-title":"Gut"},{"key":"1239_CR19","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.7314\/apjcp.2016.17.4.1701","volume":"17","author":"S Khazaei","year":"2016","unstructured":"Khazaei S, Rezaeian S, Soheylizad M, Khazaei S, Biderafsh A. Global incidence and mortality rates of stomach cancer and the human development index: an ecological study. Asian Pac J Cancer Prev. 2016;17:1701\u20134. https:\/\/doi.org\/10.7314\/apjcp.2016.17.4.1701.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1239_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053149","volume":"8","author":"Y Jin","year":"2013","unstructured":"Jin Y, Qiu MZ, Wang DS, et al. Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy. PLoS ONE. 2013;8: e53149. https:\/\/doi.org\/10.1371\/journal.pone.0053149.","journal-title":"PLoS ONE"},{"key":"1239_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/ajco.12349","volume":"11","author":"JC Jo","year":"2015","unstructured":"Jo JC, Baek JH, Koh SJ, et al. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: a single center experience in Korea. Asia Pac J Clin Oncol. 2015;11:282\u20137. https:\/\/doi.org\/10.1111\/ajco.12349.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1239_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12885-021-07919-0","volume":"21","author":"Y Liang","year":"2021","unstructured":"Liang Y, Zhao L, Chen H, et al. Survival analysis of elderly patients over 65 years old with stage II\/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study. BMC Cancer. 2021;21:196. https:\/\/doi.org\/10.1186\/s12885-021-07919-0.","journal-title":"BMC Cancer"},{"key":"1239_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc.2016.30","volume":"16","author":"A Clocchiatti","year":"2016","unstructured":"Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer. 2016;16:330\u20139. https:\/\/doi.org\/10.1038\/nrc.2016.30.","journal-title":"Nat Rev Cancer"},{"key":"1239_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2016.04.001","volume":"29","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Liu L, Chen H, et al. Comprehensive characterization of molecular Differences in Cancer between male and female patients. Cancer Cell. 2016;29:711\u201322. https:\/\/doi.org\/10.1016\/j.ccell.2016.04.001.","journal-title":"Cancer Cell"},{"key":"1239_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.607909","volume":"10","author":"M Abancens","year":"2020","unstructured":"Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual dimorphism in colon cancer. Front Oncol. 2020;10: 607909. https:\/\/doi.org\/10.3389\/fonc.2020.607909.","journal-title":"Front Oncol"},{"key":"1239_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"CH Li","year":"2020","unstructured":"Li CH, Prokopec SD, Sun RX, et al. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11:1.","journal-title":"Nat Commun"},{"key":"1239_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13293-019-0277-z","volume":"11","author":"JB Rubin","year":"2020","unstructured":"Rubin JB, Lagas JS, Broestl L, et al. Sex differences in cancer mechanisms. Biol Sex Difer. 2020;11:1\u201329.","journal-title":"Biol Sex Difer"},{"key":"1239_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s10120-016-0606-4","volume":"20","author":"N Fuse","year":"2017","unstructured":"Fuse N, Bando H, Chin K, et al. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. Gastric Cancer. 2017;20:332\u201340. https:\/\/doi.org\/10.1007\/s10120-016-0606-4.","journal-title":"Gastric Cancer"},{"key":"1239_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(18)30383-2","volume":"4","author":"T Yoshikawa","year":"2019","unstructured":"Yoshikawa T, Terashima M, Mizusawa J, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:208\u201316. https:\/\/doi.org\/10.1016\/S2468-1253(18)30383-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1239_CR30","first-page":"2312","volume":"11","author":"K Nishibeppu","year":"2021","unstructured":"Nishibeppu K, Komatsu S, Kosuga T, et al. Cumulative total S-1 dose in adjuvant chemotherapy affects the long-term outcome following curative gastrectomy for gastric cancer. Am J Cancer Res. 2021;11:2312\u20138.","journal-title":"Am J Cancer Res"},{"key":"1239_CR31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.21873\/anticanres.13215","volume":"39","author":"T Aoyama","year":"2019","unstructured":"Aoyama T, Yoshikawa T, Maezawa Y, et al. Influence of postoperative surgical complications after gastrectomy on body weight and body composition changes in patients with gastric cancer. Anticancer Res. 2019;39:1073\u20138. https:\/\/doi.org\/10.21873\/anticanres.13215.","journal-title":"Anticancer Res"},{"key":"1239_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10147-017-1089-y","volume":"22","author":"T Aoyama","year":"2017","unstructured":"Aoyama T, Sato T, Maezawa Y, et al. Postoperative weight loss leads to poor survival through because of poor S-1 efficacy in patients with stage II\/III gastric cancer. Int J Clin Oncol. 2017;22:476\u201383. https:\/\/doi.org\/10.1007\/s10147-017-1089-y.","journal-title":"Int J Clin Oncol"},{"key":"1239_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40262-021-01069-z","volume":"61","author":"K Soejima","year":"2022","unstructured":"Soejima K, Sato H, Hisaka A. Age-related change in hepatic clearance inferred from multiple population pharmacokinetic studies: comparison with renal clearance and their associations with organ weight and blood flow. Clin Pharmacokinet. 2022;61:295\u2013305. https:\/\/doi.org\/10.1007\/s40262-021-01069-z.","journal-title":"Clin Pharmacokinet"},{"key":"1239_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3349\/ymj.2019.60.2.132","volume":"60","author":"CK Roh","year":"2019","unstructured":"Roh CK, Choi YY, Choi S, et al. Single patient classifier assay, microsatellite instability, and Epstein-Barr virus status predict clinical outcomes in Stage II\/III gastric cancer: results from Classic trial. Yonsei Med J. 2019;60:132\u20139. https:\/\/doi.org\/10.3349\/ymj.2019.60.2.132.","journal-title":"Yonsei Med J"},{"key":"1239_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jso.23618","volume":"110","author":"YY Choi","year":"2014","unstructured":"Choi YY, Bae JM, An JY, et al. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J Surg Oncol. 2014;110:129\u201335. https:\/\/doi.org\/10.1002\/jso.23618.","journal-title":"J Surg Oncol"},{"key":"1239_CR36","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ijc.29449","volume":"137","author":"SY Kim","year":"2015","unstructured":"Kim SY, Choi YY, An JY, et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analyses. Int J Cancer. 2015;137:819\u201325. https:\/\/doi.org\/10.1002\/ijc.29449.","journal-title":"Int J Cancer"},{"key":"1239_CR37","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy(MAGIC) Trial. JAMA Oncol. 2017;3:1197\u2013203. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6762.","journal-title":"JAMA Oncol"},{"key":"1239_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/SLA.0000000000002803","volume":"270","author":"YY Choi","year":"2019","unstructured":"Choi YY, Kim H, Shin SJ, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II\/III gastric cancer: post hoc analysis of the Classic randomized controlled study. Ann Surg. 2019;270:309\u201316. https:\/\/doi.org\/10.1097\/SLA.0000000000002803.","journal-title":"Ann Surg"},{"key":"1239_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/ijc.26399","volume":"131","author":"JY An","year":"2012","unstructured":"An JY, Kim H, Cheong JH, Hyung WJ, Kim H, Noh SH. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer. 2012;131:505\u201311. https:\/\/doi.org\/10.1002\/ijc.26399.","journal-title":"Int J Cancer"},{"key":"1239_CR40","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/s0016-5085(99)70499-3","volume":"116","author":"H Yamamoto","year":"1999","unstructured":"Yamamoto H, Perez-Piteira J, Yoshida T, Terada M, Itoh F, Imai K, Perucho M. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology. 1999;116:1348\u201357. https:\/\/doi.org\/10.1016\/s0016-5085(99)70499-3.","journal-title":"Gastroenterology"},{"key":"1239_CR41","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdn169.","journal-title":"Ann Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01239-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01239-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01239-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T15:02:59Z","timestamp":1751036579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01239-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01239-3","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"29 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fumitaka Noji was employed by MSD.K.K. at the time of the study and is currently employed in Moderna Japan. However, MSD.K.K. and Moderna Japan are not involved in the analysis of this study. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"142"}}